Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 2

00:55 EST 25th November 2017 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 26–50 of 7,600+

Probably Relevant

Crestovo, Finch Therapeutics merge to create fully-integrated microbiome company

Finch Therapeutics Inc. is merging with fellow closely held microbiome company Crestovo to form Finch Therapeutics Group.


United Therapeutics To Present At 2017 Healthcare Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug.9, 2017 /PRNewswire/ --United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the...

Grid Therapeutics licenses antibody rights from Duke

Duke University granted its spin-out Grid Therapeutics LLC exclusive rights to all IP and patents related to complement facto...


Evox Therapeutics Appoints Antonin de Fougerolles as Chief Executive Officer

Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Dr Antonin "Tony" de Fougerolles as Read more...

ProQR licenses LUMC's antisense therapeutics IP for amyloid-beta-mediated diseases

Dutch RNA-based therapeutics start-up ProQR Therapeutics NV licensed exclusive worldwide rights to Leiden University Medical ...

Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Summit Therapeutics plc('Summit', or the 'Company')SUMMIT THERAPEUTICS TO PRESENT AT THE CANACCORD GENUITY GROWTH CONFERENCEOxford, UK, 3 August 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: ...

Siamab and BI agree to collaborate on development of antibody therapeutics for solid tumors

Siamab Therapeutics Inc. and Boehringer Ingelheim GMBH are collaborating to develop antibody therapeutics targeting tumor ass...

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that some believe could be as big a revolution as monoclonal ... This awesome article RNA as a Therapy: Reviewing the Future Generation of Therapeutics appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Anne Prener to lead Freeline Therapeutics

She joins from Gyroscope Therapeutics to take up CEO role

Former PTC Therapeutics Exec Jumps Ship to Orchard Therapeutics as CEO

  Life Sciences Jobs   ...

miRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide-Based Therapeutics Conference

BOULDER, Colo., Oct. 18, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that clinical data for its two lead product candidates, MRG-106 and MRG-201, will be presented at the DIA Oligonucleotide-Based Therapeutics Conference. The conference is being...

4D Molecular Therapeutics teams with Foundation Fighting Blindness to develop gene therapies

4D Molecular Therapeutics announced a partnership with Foundation Fighting Blindness to develop intravitreal gene therapeutics for patients with inherited retinal degenerations and dry age-related macular degeneration. 4D Molecular Therapeutics will provide access to its vector technology and manufacturing capabilities, and Foundation Fighting Blindness will identify potential academic and busines...

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’s LUNAR™ li...

ProQR Therapeutics Spins Out CNS-Focused Biotech, Amylon Therapeutics

Acer Therapeutics and Opexa Therapeutics Close Merger and Financing

-Merger to create a pre-NDA-stage, Nasdaq-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need- -Combined company, renamed Acer Therapeutics Inc., to commence trading on Nasdaq under the symbol “ACER” on September 21- -Concurrent financing of $15.7 million from Acer investor syndicate- -Ac...

Aptevo Therapeutics to sell hyperimmune commercial products

Aptevo Therapeutics has agreed to sell its three marketed hyperimmune products, WinRho SDF, HepaGam B, and VARIZIG, to Saol Therapeutics for total consideration of up to $74.5m.

The Current issue of “The view from here” is concerned with Novel Therapeutics.

The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.

ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics

Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors.As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders and will be entitled to future milestones and royalties from the products developed.Amylon will initially focus on deve...

VIDEO: Mission Therapeutics CEO On Clinical Strategy For DUB Drugs

Anker Lundemose, CEO of UK-based Mission Therapeutics, outlines the company's emerging DUBs drug discovery platform on the sidelines of the...   

Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced that it will report preclinical data on  its second product candidate, XMT-1536, in a poster to be presente...

Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune ... This awesome article Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics appeared first on Labiotech.eu. Be kind and ...

Transition Therapeutics licenses drug candidate from Eli Lilly

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. TT701 is a selective androgen receptor modulator that has been shown in a Phase 2 study to significantly increase lean body mass and a measurement of muscle more » The post T...

Critical Contrast: Aimmune Therapeutics

Aimmune Therapeutics and Novan are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitabiliy. 69.6% of Aimmune Therapeutics shares are owned by institutional investors.

Company Spotlight: PTC Therapeutics

Shares of PTC Therapeutics Inc. (PTCT) are up 69% year-to-date compared to the iShares NASDAQ Biotechnology Index's (ETF) gain of a modest 17.7%.

Neon Therapeutics Enters License Agreement With The Netherlands Cancer Institute (NCI) For Neoantigen-Based T Cell Therapeutics

  Life Sciences Jobs   ...


Quick Search
Advertisement
 

News Quicklinks